[ Impact of CCND1 A870 G polymorphism on acute adverse events in <font color="red">postoperative_4</font> <font color="red">rectal_4</font> <font color="red">cancer_4</font> <font color="red">patients_4</font> <font color="red">treated_2</font> <font color="red">with_2</font> <font color="red">adjuvant_2</font> <font color="red">concurrent_2</font> <font color="red">chemoradiotherapy_2</font> <font color="red">]_2</font> . 
<br>
<br> OBJECTIVE The purpose of this study was to investigate the association between single nucleotide polymorphism ( SNP ) of CCND1 A870 G and acute adverse events ( AEs ) in <font color="red">postoperative_5</font> <font color="red">rectal_5</font> <font color="red">cancer_5</font> <font color="red">patients_5</font> <font color="red">who_2</font> <font color="red">received_2</font> <font color="red">capecitabine_2</font> <font color="red">-_2</font> <font color="red">based_2</font> <font color="red">postoperative_2</font> <font color="red">chemoradiotherapy_2</font> <font color="red">(_2</font> <font color="red">CRT_2</font> <font color="red">)_2</font> <font color="red">._2</font> <font color="red">
<br>_1</font> METHODS <font color="red">Four_7</font> <font color="red">hundred_7</font> <font color="red">patients_7</font> <font color="red">with_7</font> <font color="red">stage_7</font> <font color="red">II_7</font> <font color="red">and_7</font> <font color="red">III_7</font> <font color="red">rectal_7</font> <font color="red">cancer_7</font> <font color="red">received_5</font> <font color="red">postoperative_5</font> <font color="red">CRT_5</font> <font color="red">of_5</font> <font color="red">capecitabine_5</font> <font color="red">with_5</font> <font color="red">or_5</font> <font color="red">without_5</font> <font color="red">oxaliplatin_5</font> <font color="red">were_1</font> <font color="red">accumulated_1</font> <font color="red">and_1</font> <font color="red">prostectively_1</font> <font color="red">studied_1</font> <font color="red">in_1</font> <font color="red">this_1</font> <font color="red">study_1</font> <font color="red">._1</font> <font color="red">The_1</font> <font color="red">patients_2</font> <font color="red">were_2</font> <font color="red">randomly_2</font> <font color="red">divided_2</font> <font color="red">into_2</font> <font color="red">two_2</font> <font color="red">groups_2</font> <font color="red">._2</font> <font color="red">Two_4</font> <font color="red">hundred_4</font> <font color="red">and_4</font> <font color="red">twenty_4</font> <font color="red">-_4</font> <font color="red">eight_4</font> <font color="red">patients_4</font> <font color="red">were_1</font> <font color="red">treated_1</font> <font color="red">with_1</font> <font color="red">concurrent_1</font> <font color="red">capecitabine_1</font> <font color="red">and_1</font> <font color="red">radiotherapy_1</font> <font color="red">(_1</font> <font color="red">Cap_1</font> <font color="red">-_1</font> <font color="red">CRT_1</font> <font color="red">)_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">172_2</font> <font color="red">patients_2</font> <font color="red">were_1</font> <font color="red">treated_1</font> <font color="red">with_1</font> <font color="red">capecitabine_1</font> <font color="red">and_1</font> <font color="red">oxaliplatin_1</font> <font color="red">plus_1</font> <font color="red">radiotherapy_1</font> <font color="red">(_1</font> <font color="red">Cap_1</font> <font color="red">-_1</font> <font color="red">Oxa_1</font> <font color="red">-_1</font> <font color="red">CRT_1</font> <font color="red">)_1</font> <font color="red">._1</font> Adverse events were graded according to the Common Terminology Criteria for Adverse Events , v. 3.0 ( CTCAE v3.0 ) . The <font color="red">genotype_1</font> <font color="red">of_1</font> <font color="red">CCND1_1</font> <font color="red">A870_1</font> <font color="red">G_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">patients_1</font> was detected by polymerase chain reaction - based restriction fragment length polymorphism ( PCR - RFLP ) analysis . The associations between the SNP and acute AEs were indicated by odds ratios ( ORs ) and 95% confidence intervals ( CIs ) , which were computed with logistic regression model . 
<br> RESULTS A total of <font color="red">136_2</font> <font color="red">patients_2</font> <font color="red">presented_1</font> <font color="red">severe_1</font> <font color="red">AEs_1</font> <font color="red">._1</font> Among them the frequencies of the three genotypes GG , GA and AA were 16.9% , 50.7% and 32.4% , compared with 24.6% , 48.1% and 27.3% , respectively , among the <font color="red">patients_1</font> <font color="red">without_1</font> <font color="red">severe_1</font> <font color="red">AEs_1</font> <font color="red">._1</font> Diarrhea was the most common AE , and <font color="red">severe_1</font> <font color="red">diarrhea_1</font> <font color="red">occurred_1</font> <font color="red">in_1</font> <font color="red">109_1</font> <font color="red">patients_1</font> <font color="red">._1</font> The frequencies of the three genotypes GG , GA and AA were <font color="red">15.6%_1</font> <font color="red">,_1</font> <font color="red">47.7%_1</font> <font color="red">and_1</font> <font color="red">36.7%_1</font> <font color="red">among_1</font> <font color="red">these_1</font> <font color="red">patients_1</font> <font color="red">,_1</font> compared with 24.4% , 49.5% and 26.1% , respectively , among <font color="red">patients_1</font> <font color="red">without_1</font> <font color="red">severe_1</font> <font color="red">diarrhea_1</font> <font color="red">._1</font> Multivariate logistic regression analysis showed a 1.66-fold increased risk for severe diarrhea in <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">AA_1</font> <font color="red">genotype_1</font> ( 95%CI 1.03 - 2.67 , P = 0.038 ) compared with the <font color="red">cases_1</font> <font color="red">with_1</font> <font color="red">GG_2</font> <font color="red">or_2</font> <font color="red">GA_2</font> <font color="red">genotypes_2</font> <font color="red">._2</font> Stratified analysis showed that in the <font color="red">Cap_1</font> <font color="red">-_1</font> <font color="red">Oxa_1</font> <font color="red">-_1</font> <font color="red">CRT_1</font> <font color="red">group_1</font> <font color="red">,_1</font> <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">AA_2</font> <font color="red">genotype_2</font> showed a 2.34-fold increased risk for severe diarrhea ( 95%CI 1.16 - 4.76 , P = 0.018 ) compared with those with <font color="red">GG_1</font> <font color="red">or_1</font> <font color="red">GA_1</font> <font color="red">genotypes_1</font> <font color="red">,_1</font> but in the <font color="red">Cap_1</font> <font color="red">-_1</font> <font color="red">CRT_1</font> <font color="red">group_1</font> <font color="red">,_1</font> the SNP was not associated with the risk of severe diarrhea . 
<br> CONCLUSIONS The genetic polymorphism of CCND1 A870 G might be a potential biomarker for predicting acute AEs in <font color="red">postoperative_2</font> <font color="red">stage_2</font> <font color="red">II_2</font> <font color="red">and_2</font> <font color="red">III_2</font> <font color="red">rectal_2</font> <font color="red">cancer_2</font> <font color="red">patients_2</font> treated with adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin .